PDCD1 and non-small cell lung carcinoma: The first large trial showed that in 100 patients with NSCLC and renal cell cancer (RCC) undergoing anti-PD-1 therapy, specific bacteria such as A. muciniphila and Alistipes indistinctus were overrepresented in the feces of patients achieving at least a stable disease [21,22].